Pharmacological inhibition of USP14 attenuates LPS-induced septic myocardial injury by rebalancing Bach1/Nrf2 signalling and mitochondrial quality control.
BACKGROUND Septic cardiomyopathy is driven by immunoinflammatory activation, oxidative stress, and mitochondrial quality-control failure. However, whether pharmacological targeting of USP14 can attenuate septic myocardial injury through Bach1/Nrf2-associated inflammatory and mitochondrial responses remains unclear. M...